المؤلفون: Harry G M Heijerman, Edward F McKone, Damian G Downey, Eva Van Braeckel, Steven M Rowe, Elizabeth Tullis, Marcus A Mall, John J Welter, Bonnie W Ramsey, Charlotte M McKee, Gautham Marigowda, Samuel M Moskowitz, David Waltz, Patrick R Sosnay, Christopher Simard, Neil Ahluwalia, Fengjuan Xuan, Yaohua Zhang, Jennifer L Taylor-Cousar, Karen S McCoy, Karen McCoy, Scott Donaldson, Seth Walker, James Chmiel, Ronald Rubenstein, Deborah K. Froh, Isabel Neuringer, Manu Jain, Kathryn Moffett, Jennifer L. Taylor-Cousar, Bruce Barnett, Gary Mueller, Patrick Flume, Floyd Livingston, Nighat Mehdi, Charlotte Teneback, John Welter, Raksha Jain, Dana Kissner, Kapilkumar Patel, Francisco J. Calimano, Jimmy Johannes, Cori Daines, Thomas Keens, Herschel Scher, Subramanyam Chittivelu, Sudhakar Reddivalam, Ross Carl Klingsberg, Larry G. Johnson, Stijn Verhulst, Patricia Macedo, Damien Downey, Gary Connett, Edward Nash, Nicholas Withers, Timothy Lee, Marleen Bakker, Harry Heijerman, Francois Vermeulen, Christiane Knoop, Elke De Wachter, Renske van der Meer, Petrus Merkus, Christof Majoor

المساهمون: Pulmonology, AII - Inflammatory diseases, Clinical sciences, Physiotherapy, Human Physiology and Anatomy, Pediatrics

المصدر: Lancet, 394(10212), 1940-1948. Elsevier Limited
VX17-445-103 Trial Group 2019, ' Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial ', Lancet, vol. 394, no. 10212, pp. 1940 . https://doi.org/10.1016/S0140-6736(19)32597-8
Lancet
The Lancet, 394(10212), 1940. Elsevier Limited

مصطلحات موضوعية: Male, Indoles, Pyrrolidines, Cystic Fibrosis, Pyridines, Clinical Trial, Phase III, Phases of clinical research, Cystic Fibrosis Transmembrane Conductance Regulator, 030204 cardiovascular system & hematology, Quinolones, Aminophenols, Cystic fibrosis, law.invention, Ivacaftor, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, 030212 general & internal medicine, Pyridines/administration & dosage, Non-U.S. Gov't, Chloride Channel Agonists, Sweat, Child, Chloride Channel Agonists/administration & dosage, Medicine(all), biology, Research Support, Non-U.S. Gov't, Lumacaftor, General Medicine, Indoles/administration & dosage, Clinical Trial, Cystic fibrosis transmembrane conductance regulator, Pyrrolidines/administration & dosage, Quinolones/administration & dosage, Randomized Controlled Trial, Combination, Drug Therapy, Combination, Female, medicine.drug, medicine.medical_specialty, Adolescent, Research Support, Article, Benzodioxoles/administration & dosage, Sweat/chemistry, N.I.H, 03 medical and health sciences, Phase III, Research Support, N.I.H., Extramural, Double-Blind Method, Drug Therapy, Internal medicine, Journal Article, medicine, Aminophenols/administration & dosage, Humans, Benzodioxoles, business.industry, Extramural, medicine.disease, Pyrazoles/administration & dosage, Clinical trial, Regimen, chemistry, biology.protein, Pyrazoles, Cystic Fibrosis Transmembrane Conductance Regulator/genetics, sense organs, Cystic Fibrosis/drug therapy, business

وصف الملف: application/pdf; text/plain

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221e25362cf07bd88d1d3728962d9a50
http://www.scopus.com/inward/record.url?scp=85074786708&partnerID=8YFLogxK

المؤلفون: VX17-445-103 Trial Group

مصطلحات موضوعية: Male, Medicine(all), Adolescent, Research Support, Non-U.S. Gov't, Clinical Trial, Phase III, Indoles/administration & dosage, Pyrazoles/administration & dosage, Benzodioxoles/administration & dosage, Pyrrolidines/administration & dosage, Sweat/chemistry, Double-Blind Method, Research Support, N.I.H., Extramural, Quinolones/administration & dosage, Randomized Controlled Trial, Aminophenols/administration & dosage, Journal Article, Cystic Fibrosis Transmembrane Conductance Regulator/genetics, Humans, Drug Therapy, Combination, Female, Cystic Fibrosis/drug therapy, Pyridines/administration & dosage, Child, Chloride Channel Agonists/administration & dosage

وصف الملف: image/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od_____10691::89138b60eee52c990cd8474204258594
https://dspace.library.uu.nl/handle/1874/391989

المؤلفون: Johansson, Ann-Sofie

مصطلحات موضوعية: Disease models, animal, Leukemia, T-cell, Lymphoma, T-cell, Moloney murine leukemia virus -- genetics, Antineoplastic agents, alkylating -- administration & dosage, Antineoplastic combined chemotherapy protocols -- therapeutic use, Cyclooxygenase inhibitors -- administration & dosage, Cyclophosphamide -- administration & dosage, Precursor cell lymphoblastic leukemia-lymphoma -- drug therapy, Pyrazoles -- administration & dosage, Sulfonamides -- administration & dosage

URL الوصول: http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-35195

Degree: Diss. (sammanfattning) Umeå : Umeå universitet, 2010

المؤلفون: Meunier, Andreas

مصطلحات موضوعية: Anti-inflammatory agents, non-steroidal -- administration & dosage, Arthroplasty, replacement, knee -- adverse effects, Blood loss, surgical -- prevention & control, Cyclooxygenase inhibitors -- administration & dosage, Cyclooxygenase inhibitors -- adverse effects, Fracture healing -- drug effects, Isoxazoles -- adverse effects, Pain, postoperative -- drug therapy, Pyrazoles -- administration & dosage, Sulfonamides -- administration & dosage

URL الوصول: http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-15114

Degree: Diss. (sammanfattning) Linköping : Linköpings universitet, 2008

المؤلفون: Fleischmann, Roy, Tannenbaum, Hyman, Patel, Neha P, Notter, Marianne, Sallstig, Peter, Reginster, Jean-Yves

المصدر: BMC Musculoskeletal Disorders, 9, 32 (2008)

مصطلحات موضوعية: Aged, Arthralgia/etiology/prevention & control, Canada, Cardiovascular Diseases/chemically induced, Cyclooxygenase 2 Inhibitors/administration & dosage/adverse effects, Diclofenac/administration & dosage/adverse effects/analogs & derivatives, Double-Blind Method, Drug Administration Schedule, Europe, Female, Gastrointestinal Diseases/chemically induced, Humans, Liver Diseases/chemically induced, Male, Middle Aged, Osteoarthritis/complications/drug therapy, Pain Measurement, Pyrazoles/administration & dosage/adverse effects, Sulfonamides/administration & dosage/adverse effects, Time Factors, Treatment Outcome, United States, Human health sciences, General & internal medicine, Sciences de la santé humaine, Médecine générale & interne

Relation: urn:issn:1471-2474

URL الوصول: https://orbi.uliege.be/handle/2268/20405

المؤلفون: Jeffrey I. Weitz, Martin H. Prins, Akos F. Pap, Alexander T. Cohen, Peter Verhamme, Philip S. Wells, Jan Beyer-Westendorf, Anthonie W. A. Lensing, Rodney Hughes, Paolo Prandoni, Saskia Middeldorp, Mila Trajanovic, Roopen Arya, Nils Kucher, Henri Bounameaux

المساهمون: ACS - Pulmonary hypertension & thrombosis, Vascular Medicine, MUMC+: KIO Kemta (9), RS: CAPHRI - R5 - Optimising Patient Care, Epidemiologie, University of Zurich, Beyer-Westendorf, Jan

المصدر: Thrombosis research, 149, 29-37. Elsevier Limited
Thrombosis Research, 149, 29-37. Elsevier Science
Thrombosis Research, Vol. 149 (2017) pp. 29-37
Beyer-Westendorf, J, Lensing, A W A, Arya, R, Bounameaux, H, Cohen, A T, Wells, P S, Middeldorp, S, Verhamme, P, Hughes, R, Kucher, N, Pap, A F, Trajanovic, M, Prins, M H, Prandoni, P & Weitz, J I 2016, ' Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials ', Thrombosis Research . https://doi.org/10.1016/j.thromres.2016.11.014

مصطلحات موضوعية: Male, 2720 Hematology, 030204 cardiovascular system & hematology, law.invention, Rivaroxaban/administration & dosage/adverse effects/therapeutic use, Cohort Studies, DOUBLE-BLIND, 0302 clinical medicine, Randomized controlled trial, law, Hemorrhage/chemically induced, 030212 general & internal medicine, 610 Medicine & health, anticoagulation, rivaroxaban, ORAL ANTICOAGULANTS, ddc:616, DABIGATRAN, Pyridones/administration & dosage/adverse effects/therapeutic use, Hematology, Middle Aged, OPEN-LABEL, CANCER, Treatment Outcome, Cohort, Apixaban, Female, medicine.drug, Cohort study, Adult, medicine.medical_specialty, Pyridones, RANDOMIZED CONTROLLED-TRIALS, Factor Xa Inhibitors/administration & dosage/adverse effects/therapeutic use, venous thromboembolism, apixaban, Hemorrhage, Thrombophilia, Pyrazoles/administration & dosage/adverse effects/therapeutic use, 03 medical and health sciences, VITAMIN-K ANTAGONISTS, Internal medicine, medicine, Humans, cardiovascular diseases, METAANALYSIS, Aged, Rivaroxaban, business.industry, Patient Selection, 10031 Clinic for Angiology, RIVAROXABAN, medicine.disease, Confidence interval, Surgery, Relative risk, Pyrazoles, ACUTE VENOUS THROMBOEMBOLISM, business, Venous Thromboembolism/drug therapy, Factor Xa Inhibitors

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db0948ae7c80bf0f9d86902bd51f748b
https://doi.org/10.1016/j.thromres.2016.11.014

المؤلفون: Gregory Y.H. Lip

المصدر: Lip, G Y H 2019, ' The safety of NOACs in atrial fibrillation patient subgroups : A narrative review ', International Journal of Clinical Practice, vol. 73, no. 2, e13285 . https://doi.org/10.1111/ijcp.13285
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

مصطلحات موضوعية: Stroke/etiology, medicine.medical_specialty, Pyridines, Pyridones, Rivaroxaban/administration & dosage, Patient subgroups, MEDLINE, Administration, Oral, Hemorrhage, 030204 cardiovascular system & hematology, Warfarin/adverse effects, 03 medical and health sciences, 0302 clinical medicine, Rivaroxaban, Risk Factors, Thiazoles/administration & dosage, Hemorrhage/chemically induced, Atrial Fibrillation, medicine, Humans, Dabigatran/administration & dosage, cardiovascular diseases, 030212 general & internal medicine, Pyridines/administration & dosage, Intensive care medicine, Stroke, Anticoagulants/administration & dosage, Pyridones/administration & dosage, business.industry, Warfarin, Age Factors, Anticoagulants, Atrial fibrillation, General Medicine, medicine.disease, Pyrazoles/administration & dosage, Dabigatran, Clinical trial, Thiazoles, Clinical Trials, Phase III as Topic, Pyrazoles, Narrative review, business, Atrial Fibrillation/complications, Major bleeding, medicine.drug

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c31a03596faff0bfee86879256cde1c4
https://vbn.aau.dk/ws/files/293589076/The_safety_of_NOACs_in_atrial_fibrillation_patient_subgroups_A_narrative_review.pdf

المؤلفون: Loriot, Yohann, Necchi, Andrea, Park, Se Hoon, Garcia-Donas, Jesus, Huddart, Robert, Burgess, Earle, Fleming, Mark, Rezazadeh, Arash, Mellado, Begoña, Varlamov, Sergey, Joshi, Monika, Duran, Ignacio, Tagawa, Scott, Zakharia, Yousef, Zhong, Bob, Stuyckens, Kim, Santiago-Walker, Ademi, De Porre, Peter, O’Hagan, Anne, Avadhani, Anjali, Siefker-Radtke, Arlene, Houédé, Nadine

المساهمون: Loriot, Y, Necchi, A, Park, Sh, Garcia-Donas, J, Huddart, R, Burgess, E, Fleming, M, Rezazadeh, A, Mellado, B, Varlamov, S, Joshi, M, Duran, I, Tagawa, St, Zakharia, Y, Zhong, B, Stuyckens, K, Santiago-Walker, A, De Porre, P, O'Hagan, A, Avadhani, A, Siefker-Radtke, Ao, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Fondazione IRCCS Istituto Nazionale dei Tumori, Samsung Medical Center Sungkyunkwan University School of Medicine, Institute Division of Hematology/Oncology, Centro Integral Oncologico Clara Campal, Academic Radiotherapy Unit, Institute of cancer research, The Levine Cancer Institute, Virginia Oncology Associates, University of Louisville, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Scientific Information Analyses, Siberian Research Institute of Cheese-Making, Barnaul, Russia, Department of Veterinary and Biomedical Sciences, Penn State Cancer Institute, The Pennsylvania State University, 115 Henning Building, University Park, PA 16802, USA., Marqués de Valdecilla University Hospital [Santander], Weill Medical College of Cornell University [New York], Department of Pediatrics and Holden Comprehensive Cancer Center [Iowa City, USA], University of Iowa [Iowa City]-Carver College of Medicine, University of Iowa, Janssen Research & Development [Spring House, PA, USA], Janssen Pharmaceutica [Beerse], Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)

المصدر: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2019, 381 (4), pp.338-348. ⟨10.1056/NEJMoa1817323⟩

مصطلحات موضوعية: Adult, Urologic Neoplasms, Metastatic Urothelial Carcinoma, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, medicine.disease_cause, 03 medical and health sciences, 0302 clinical medicine, Immune system, Erdafitinib, Quinoxalines, Humans, MESH: Quinoxalines / administration & dosage, Receptors, Fibroblast Growth Factor / antagonists & inhibitors, Receptors, Fibroblast Growth Factor / genetics, Urologic Neoplasms / drug therapy, Medicine, 030212 general & internal medicine, Progression-free survival, Neoplasm Metastasis, Urothelium, Receptor, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Mutation, MESH: Antineoplastic Agents / administration & dosage, Protein Kinase Inhibitors / administration & dosage, Pyrazoles / administration & dosage, business.industry, General Medicine, Middle Aged, Protein-Tyrosine Kinases, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, Receptors, Fibroblast Growth Factor, Progression-Free Survival, 3. Good health, Treatment Outcome, Fibroblast growth factor receptor, Cancer research, Pyrazoles, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffcfc170e758d7ea02e09dd18fd05524

المؤلفون: Elaine Kilgour, Marie Cullberg, Jean-Charles Soria, Michael F. Berger, David Ferry, Fabrice Andre, A. Nigel Brooks, Ronglai Shen, Paul K. Paik, Claire Rooney, Neil R. Smith, Donal Landers, Alastair Mathewson, Paul Frewer

المصدر: Paik, P K, Shen, R, Berger, M F, Ferry, D, Soria, J-C, Mathewson, A, Rooney, C, Smith, N R, Cullberg, M, Kilgour, E, Landers, D, Frewer, P, Brooks, N & André, F 2017, ' A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 23, no. 18, pp. 5366-5373 . https://doi.org/10.1158/1078-0432.CCR-17-0645

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Pathology, Lung Neoplasms, Piperazines, 0302 clinical medicine, Carcinoma, Squamous Cell/drug therapy, Gene duplication, Clinical endpoint, Medicine, Neoplasm Metastasis, Manchester Cancer Research Centre, Middle Aged, Antineoplastic Agents/administration & dosage, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Benzamides, Carcinoma, Squamous Cell, Female, Chromosomes, Human, Pair 8, medicine.medical_specialty, Antineoplastic Agents, Article, 03 medical and health sciences, Genetic Heterogeneity, Internal medicine, Carcinoma, Benzamides/administration & dosage, Humans, Receptor, Fibroblast Growth Factor, Type 1, Adverse effect, Lung Neoplasms/drug therapy, Aged, Neoplasm Staging, business.industry, Receptor, Fibroblast Growth Factor, Type 1/genetics, Gene Expression Profiling, ResearchInstitutes_Networks_Beacons/mcrc, Gene Amplification, Cancer, Piperazines/administration & dosage, Sequence Analysis, DNA, medicine.disease, Pyrazoles/administration & dosage, Gene expression profiling, stomatognathic diseases, 030104 developmental biology, Pharmacodynamics, Pyrazoles, Neoplasm Grading, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::990f2a483a46e22776bff83e60c537f8
https://research.manchester.ac.uk/en/publications/3279fad9-f754-4e8a-b3e0-f835a5a0b263

المؤلفون: Andrea Varga, Antoine Hollebecque, Rastilav Bahleda, Anas Gazzah, Christophe Massard, Sandrine Aspeslagh, Jean-Charles Soria, Anna Spreafico, Michele Reni, Kunwar Shailubhai

المساهمون: Medical Oncology

مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Lung Neoplasms, Antimetabolites, Antineoplastic/administration & dosage, Carcinoma, Non-Small-Cell Lung/drug therapy, Toxicology, Deoxycytidine, Gastroenterology, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Pharmacology (medical), Drug Interactions, Middle Aged, Cyclin-Dependent Kinases, Treatment Outcome, Tolerability, 030220 oncology & carcinogenesis, Peritoneal mesothelioma, Female, medicine.drug, Antimetabolites, Antineoplastic, medicine.medical_specialty, Maximum Tolerated Dose, Neutropenia, Cyclin-Dependent Kinases/antagonists & inhibitors, 03 medical and health sciences, Refractory, Pharmacokinetics, Internal medicine, medicine, Humans, Lung Neoplasms/drug therapy, Deoxycytidine/administration & dosage, Aged, Pharmacology, business.industry, Antineoplastic Combined Chemotherapy Protocols/adverse effects, medicine.disease, Pyrazoles/administration & dosage, Gemcitabine, Quinazolines/administration & dosage, Neoplasms/drug therapy, Regimen, 030104 developmental biology, Drug Resistance, Neoplasm, Concomitant, Quinazolines, Pyrazoles, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42306b90b467bedc036686d59e41b35d
https://hdl.handle.net/20.500.14017/91e1653b-3c7b-4d0b-abd1-66ca3def9be4